Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.

Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, reduced the risk of tumor recurrence or death by 49% over five years in a ...

The four-year trial of about 70 children with "dismal prognoses" in eight hospitals across Australia will test the safety and ...

Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: boosting the immune system to better fight tumors during cancer treatment.

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The fate of an important breakthrough in cancer immunotherapy treatment remains in the balance following an announcement earlier this week that the Department of Health and Human Services will cancel ...

Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA.

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or causing death by nearly half compared with Keytruda alone.

Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively with tumors and deliver mRNA therapy with minimal off-target effects.